The 3 adrenergic substances, epinephrine, levarterenol and isopropylarterenol, were injected into a coronary artery of anestlietized dogs while recording the coronary artery flow (electromagnetic meter) and pi'cssurc. The effects of these substances on the peripheral coronary pressure (PCP) were recorded by occluding the flow proximal to the pressure gage. All 3 substances caused a qualitatively similar increase in myocardial contraction and dilation of the coronary arterioles.
I T HAS BEEN postulated that arterenol
does not have as much stimulant effect upon the myocardium as does epinephrine; therefore, the former has been favored in the treatment of hypotensive states and coronary occlusion where it is desirable to improve the arterial blood pressure by peripheral vaso-<:onstriction without increasing excessively the myocardial metabolism. 1 This study was designed to explore this hypothesis by evaluating the effects of epinephrine and arterenol on the coronary ivrtcrioles and on the contractility of the myocardium and to evaluate the effect of a typical adrenergic blocking drug, azapetine {Ilidar), on these responses. Isopropylarterenol was included in the group of adrenergic drugs because it appears to have a vasomotor action in skeletal muscle vascular beds similar to the dilator phase of epinephrine.-
METHODS
The studies were done upon open-chested, mongrel dogs, premedieated with morphine sulfate 2.0 jng./Kg. subcutaneously and anesthetized with 0.25 ml./Kg. of a solution containing sodium pentobarbital, Dial, and Urethane. Positive pressure artificial respiration was administered with air. Oxygen was added continuously by tracheal catheter at the into of 0.S L./min. The heart was exposed by removal of the anterior halves of the left fourth and fifth ribs and was suspended in a pericardial cradle.
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Blood was obtained from a cannula in the left carotid artery, passed through a cannulating type, electromagnetic flowmetcr and into a cannula inserted in the descending ramus of the left coronary artery about 2 cm. from the bifurcation of the common artery. The flowmeter used a 200 cycle sinusoidal A. C. carrier frequency, which was adequate to reproduce the phasic flow changes occurring during the cardiac cycle. 1 Clotting was prevented by heparin in 5.0 mg./Kg. initial doses and 0.5 mg./ Kg./half-hour sustaining doses. Coronary perfusion pressure and brachial artery (aortic) pressure were recorded with Statham P23 strain gages. These phasic flows and pressures were inscribed upon a Sanborn Poly-Viso direct-writing recorder. The flow and pressure tracings were measured at 3 points in the cardiac cycle (see figure 1) : end of diastole D; at the peak effect on the flow of isometric contraction 7; and at the end of systole S.
In addition, we recorded the peripheral coronary pressure (PCP) by occluding the coronary flow proximal to the manometer which was recording the coronary perfusion pressure. 4 "' The systolic and diastolic pressures in the PCP curves were measured after the pressures had fallen to an approximately stable range (second to fourth heart beat after occlusion); and the curves were also analyzed for changes in contour. In all experiments an electrocardiogram was recorded.
These various measurements were made twice for each drug injection: during a control period and at the moment of maximal effect (experimental). Each group of measurements was made as nearly as possible on cardiac cycles occurring during the same phase of the respirator}' cycle. One, 3, and 10 MKdoses of the 3 adrenergie drugs (epinephrine, levarterenol, and isopropylarterenol) were dissolved in 1 ml. of saline and injected intraartcrially over a period of 1 sec. This scries of 9 injections was then repeated after intracoronary artery injections of 0.3, 1.0, 3.0, 10, 30, and 100 mg. of azapetine (Ilidar). The Ilidar, which was in a concentration of 10 mg./ml., was injected at a rate of 10 ml./min. The smaller doses of adrenergic drugs were omitted if they became blocked. Occasionally the initial 653 Circulation Research, Volume IV, iVorrmbcr Wbd (>54 ADREXERGIC EFFECTS ON CORONARY CIRCULATION small doses were repeated at the end of a series, to cheek on the possibility of blockade becoming less effective during the course of the 9 injections. Coronary arteriolar dilation was considered to have occurred when the peripheral resistance (coronary perfusiou pressure -7-coronary artery flow), measured at the end of diastole, decreased. This point in the heart cycle was chosen for estimating arteriolar dilation since at this moment extra vascular compression is at a minimum and is undergoing a minimum change with time and since the inflow is minimally influenced by changes in the volume of blood contained in the arteries distal to the meter Mean flows are of no value in estimating coronary arteriolar constriction or dilation, since in addition to this parameter mean flow is influenced also by the varying extravascular compression during systole and early diastole and by the varying duration of diastole with relation to that of the cj'cle.
Increased myocardial contraction is defined, for the purposes of this paper, as a more rapid and greater degree of shortening of the myocardial fibers. Augmentation of the systolic rise of intramyocardial tension occurring without significant rise of aortic systolic pressure would be indicative of such increased contraction. Qualitative evidence of increased systolic intramyoeardial tension would be: (a) The occurrence in the flow curves of a greater degree of reduction of inflow or the appearance of backflow during isometric contraction and an increase in the computed resistance to inflow at the endo f systole, (b) the observation in the pressure curves of a shortening of the ejection phase of systole, and (c) the registration in the PCP curves of an increase in the slope of the rise and fall and an elevation of the peak systolic pi'essure. 7 
RESULTS
Eleven experiments were attempted; of these two showed no responses to any of the drugs and were discarded. The flow curves were unsatisfactory in 4 of the dogs. Five experiments were considered technically satisfactory and form the basis for this paper.
Control Data Data Before Injection of Adrenergic Drug.
The pressures and flows were measured in 43 periods preceding each injection of the adrenergic substances in the 5 successful experiments. The averages and ranges for these data for the end of diastole were: pressure 111.8 (50 to 142) mm. Hg, flow 48.1 (11 to 92) ml./min., and resistance 2.9 (1.1 to 6.8) PRU; and for the end of systole they were: pressure 143.0 (100 to 180) mm. Hg, flow 17.5 (-19 to +58) ml./min., and resistance 9.1 (1.3 to41.7) PRU.
Effects (f Adrenergic Drugs on Resistance to
Floiv at End cf Diastole. In all cases, within 5 to 10 sec. after the injection of the adrenergic drugs, the flow at the end of diastole began to increase and the resistance at this same moment in the heart cycle (table 1, A) began to decrease; the maximum effect was reached in 15 to 20 sec. and an additional period of 30 to 100 sec. was required for restoration to control values. The decrease in resistance was slightly more marked with isopropylarterenol and slightly less prominent with arterenol than with epinephrine. In many of the records isopropylarterenol and, to a lesser extent, epinephrine increased the flow at the end of diastole before producing effects attributable to change of contraction, whereas with arterenol the reverse was true. The larger doses caused a more prolonged decrease in resistance and elevation of systemic pressure but did not shorten the time for the maximum effect to be reached or cause an appreciably greater amplitude of response. The elevation of systemic arterial pressure always occurred 10 to 15 sec, after the maximum effect on coronary diastolic resistance had been reached, and so did not interfere with interpretation of the cardiac effects of the drugs.
Effects of Saline on Resistance at End of
Diastole. Saline injections caused minimal decreases of apparent resistance at the end of diastole which reached a maximum in 5 to 10 sec. and returned to control within a total of 10 to 15 sec. after the beginning of injection. Thus, artifacts caused by the injections could readily be differentiated from responses to the drugs.
Effects of Adrenergic Drugs on Resistance at
End. of Systole. In most cases the apparent resistance at the end of systole increased. The results were erratic, however, due probably in part to difficulties in reading a satisfactory point on a line of rapid slope and in part to artifacts caused by inertia effects in the tubing system and the coronary artery.
Effects of Adrenergic Drugs Dvring Isometric
Contraction. Normally, coincident with the onset of isometric contraction, the rate of inflow rapidly declined toward 0 ( fig. 1 ) and occasionally a small amount of backflow was noted (table 1, JB2). This was accompanied by a rise in the coronary perfusion pressure, which was probably a "water hammer" effect. Consistently, the smallest doses of all 3 adrenergic drugs intensified this effect so that in mast cases a rather large component of backflow was recorded, accompanied by an accentuated "water hammer" effect on coronary perfusion pressure. These effects were slightly more marked with arterenol and epincphrine than with isopropylartereiiol.
lift eels of Adrenergic Drugs irn tlic Periplicral Coronary Pressure and on the Ejection Phase.
Jn the PCI* curves the maximal pressure during systole was significantly increased and the diastolic pressure was usually lowered (table 1) and the pressures rase and fell more abruptly with the heart cycle ( fig. 1 ). In the aortic pressure curves the duration of isometric contraction was not significantly altered, but the ejection phase was significant!}' shortened and the pressure rose more abruptlj'.
Other Effects of the Adrenergic Drugs. The electrocardiographs tracings showed that arterenol in the 3 and 10 Mg-doses frequently caused ventricular premature beats. Either no change of heart rate or a slight cardiac slowing was noted.
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FIG. 1.
Simultaneous records of the effects of 1 /jg. intracoronary arlery injection of epinephrinc 1 , levarlerenol, and isopropylarterenol on aortic pressure BP, coronary blood flow F t and either |>er-fusion pressure or peripheral pressure CP in the descending raraiis of (he coronary artery. For each drug the center panels 2, 5 and S and the first halves of the other panels record flow and perfusion pressure. The last halves of panels 1, 4, 7, 3, 6 and 9 record the peripheral coronary pressure. The periods of injection of an adrenergic substance are indicated by the short segment of horizontal lino above the arrow label \ed Injection in panels 2, 5 and 8. Ordinate values give the pressure in mm. Hg and flow in nil./min. Time between heavy vertical lines is 1 sec. at slow speed (panels 2, 5 and S) and ().] sec. in the other panels. Panels 3, 6 and 9 were recorded at the moment of maximum effect. D = end of diastole; Si •=• end of systole (onset of protodiastole) for the periods when coronary flow is being recorded; Sj = midystolic peak pressure on the peripheral pressure curve; 7 = point of maximal reduction of inflow or of maximum backflow during isometric contraction. These are the points in the curves at which the measurements, given in table 1, were made.
Effects of A drenergic Blockade
Ilidar produced no revei-sal of the adrenergic effects such as is seen in skeletal muscle; there was a lessening of the responses to all 3 adrenergic drugs with increasing doses of Ilidar. With 100 mg. of Ilidar the responses to 1, 3 and 10 pg. of the adrenergic drugs could be blocked completely (table 2). As the doses were progressively increased, the Ilidar caused cardiac slowing and occasional ventricular premature beats. Of 9 experiments, ventricular fibrillation or standstill occurred after the following doses of Ilidar: 3 mg., 2 dogs; 10 mg., 2 dogs; and 30 mg., 4 dogs. One dog survived 300 mg. Counter shock and massage were unable to revert the fibrillation. resistance at the end of diastole, which ranged from an average of 81 per cent of control PRU for the 1 mg. dose down to 43 per cent of control PRU for the 30 mg. dose, but had no distinct effect on the other parameters.
DISCUSSION
In the latter part of diastole extravascular compression is changing minimally, and there are minimal inertia effects due to sudden fluctuations of aortic pressure. Furthermore, in our experiments, the aortic diastolic pressures in the experimental period were, in each case, essentially the same as those in the control period. In view of these considerations, we believe we can interpret changes of resistance, measured at the end of diastole, as a reasonably reliable estimate of the extent of contraction or relaxation of the coronary arterioles. On the basis of our data we believe that all 3 adrenergic substances caused a small degree of coronary arteriolar dilation. Since isopropylarterenol and, to a lesser extent,' epinephrine caused a slightly greater degree of dilation and at times induced dilation before other changes referable to contractility were noted, it is probable that the dilation was, at least in part, a direct effect of these substances on the arterioles.
All 3 substances caused a markedly greater increase of intramyocardial tension during systole as estimated from the effects on flow during isometric contraction, resistance at the end of systole, abruptness of relaxation and contraction and amplitude of the peripheral coronary systolic pressure. While changes in any one of these might have minimal significance, the coincident change in all four and the consistency with which they wore noted with all 3 adrencrgic drugs makes it reasonably certain that all 3 substances caused increased myocardial contraction as defined earlier in this paper. The increased contraction was least prominent with isopropylarterenol; with arterenol the effect was at least equal to and perhaps more prominent than that with epinephrine.
SUMMARY
Epinephrine, levarterenol and isopropylarterenol cause markedly different vasomotor responses in many vascular beds, particularly that of skeletal muscle. However, in the coronary vascular bed they are qualitatively similar.
All 3 cause a relatively small dilation of the coronary arterioles, as manifested by decreases in resistance to flow in the coronary vascular lied, measured at the end of diastole; and all 3 increase to a marked degree myocardial contraction, as indicated by the vigor and abruptness of contraction and the rapidity and completeness of relaxation of the myocardium. Levarterenol shows a greater tendency than the others to cause premature ventricular beats, to increase myocardial contraction and a slightly lesser tendency to cause coronary arteriolar dilation.
The primary effect of adrenergic blockade (llidar) is to reduce progressively the above effects at extremely high doses. The intracoronary artery injections of the larger doses of llidar usually cause a moderate dilation of the coronary arterioles, cardiac irregularities and often ventricular fibrillation.
The greater effectiveness in hypotensive states of arterenol, as compared with epinephrine, would appear, therefore, to be due to differences in their systemic rather than their cardiac effects since the direct effect on the myocardium seems to be, if anything, more marked with arterenol than with epinephrine.
SUMMAUIO EX LVTERLIXGTA Epinephrina, levarterenol, e isopropylarterenol evoca marcatemente differente responsas vasomotori in le vasculatura del musculos skeletal e etiam in multe altere vasculaturas. Tamen, in le vasculatura coronari lor effectos es qualitativemente simile.
Le '.i drogas causa un relativemente leve dilatation del arteriolas coronari, manifesto in reductiones del resistentia al fluxo in le vasculatura coronari mesurate al fin del diastole; e le 3 drogas causa un marcate augmento del contraction myocardial, manifesto in le abrupte vigor del contraction e in le rapiditate e le completessa del relaxation del myoeardio. Levarterenol monstra un plus grande tendentia que epinephrina e isopropylarterenol a causar prematur pulsos ventricular e a augmentar le contraction myocardial e un levemente minus forte tendentia a causar dilatation del arteriolas coronari.
Le effecto primari de blocage adrenergic (Ilidar) es reducer progressivemente le supradescribite effectos, si le agente de blocage adrenergic es active in extrememente alte doses. Injectiones del plus grande doses de Ilidar in le arterias coronari causa usualmente un moderate grado de dilatation del arteriolas coronari, irregularitates cardiac, e frequentemente fibrillation ventricular.
Le plus grande efficacia in statos hypotensive quc distingue arterenol de epinephrina pare per consequente resultar de differentias del effectos systemic plus tosto que cardiac in le caso del duo agentes, proque le dirccte effecto super le myocardio es apparentemente plus marcate in le caso de arterenol que in le caso de epinephrina. Levarterenol (arterenol, norepinephrine, levophed bitartratc) was supplied in 4 ml. ampules containing 0.2 pur cent (expressed as the salt). Isopropylarterenol (isoproterenol, Isuprel) was supplied ;us the hydrochloridc. Doses of both arc expressed in terms of the base. Both were obtained from Winthrop Laboratories, Inc., Baltimore, Md.
Azapetine (Ilidar hydroehloride) was supplied in 5 ml. ampules containing 10 mg./ml. by HoffmannLaRoche, Inc., Nutley, New Jersey. Doses aiv expressed in terms of the hydrochloride.
The intravenous anesthetic was composed of equal parts of: (1) a solution containing 60 nig./ml. of sodium pentobarbital and (2) Dial with Urethane. The latter contains in each ml.: Diallylbarbiturie acid 0.1 Cm., Urethane 0.4 Cm., and monoethylurea 0.4 Gin., and was supplied by Ciba Pharmaceutical Products, Inc., Summit, New Jersey.
